Other Phase 3 trials, including PAOLA-1, PRIMA, and VELIA, also demonstrated the benefits of PARP inhibitors in newly diagnosed advanced EOC patients with tumour HRD [12, 18]. The gene discussed is PARP1; the disease is neoplasm.